Acceleron Pharma, Inc. (XLRN)
| Market Cap | 10.85B |
| Revenue (ttm) | 112.76M |
| Net Income (ttm) | -254.85M |
| Shares Out | 60.70M |
| EPS (ttm) | -4.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,021,458 |
| Open | 179.71 |
| Previous Close | 179.68 |
| Day's Range | 178.75 - 178.75 |
| 52-Week Range | 108.82 - 189.99 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 179.10 (+0.2%) |
| Earnings Date | Nov 4, 2021 |
About XLRN
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candida...
Financial Performance
In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 179.10, which is an increase of 0.20% from the latest price.
News
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed fund...
Is Merck's Planned Acquisition of Acceleron in Trouble?
There's nothing to worry about with a recent delay.
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer
NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed fund...
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)
Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.
Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma I...
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bl...
Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck
JERSEY, Channel Islands--(BUSINESS WIRE)--Darwin Global Management Limited (“Darwin Global”), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares...
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares
NEW YORK--(BUSINESS WIRE)-- #Acceleron--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Accelero...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action...
Holocene Advisors says Merck's offer undervalues Acceleron
Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalues...
Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
NEW YORK--(BUSINESS WIRE)--Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”)...
Is an Acquisition of Acceleron a Smart Move for Merck?
Merck will pick up a promising pipeline candidate with the deal.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Ac...
New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Acceleron Pharma Inc. (NASDAQ: XLRN) ...
With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision
Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blo...
ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acceleron Pharma I...
Activist Investor Thinks Merck Undervalues Acceleron Buy
Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag. Related: Merck Seals Acceler...
Core PCE Inflation Stays at Record-High in August
Core PCE Inflation Stays at Record-High in August.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
NEW YORK--(BUSINESS WIRE)--Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) ...